MESI — Automated Oscillometric ABI (PAD screening)
Evidence-supportedBgradePlausibility · Plausible / established (narrow)Sensing Physics
Evidence-supported · Evidence-supported
Cleared/validated automated oscillometric ABI measurement for peripheral artery disease screening, including in non-specialist settings.
Off-label · Not established (ungraded)
General 'vascular-age' or longevity scoring derived from the device beyond PAD screening.
The MESI ABPI MD is an automated oscillometric ABI meter for peripheral artery disease (PAD) screening that computes the ankle-brachial index from simultaneous limb-pressure cuffs rather than manual hand-held Doppler. ABI itself is a guideline- and USPSTF-recognized vascular index, and the automated MESI version has been validated against the Doppler reference in multicentre data and assessed in systematic-review work on portable ABI screening systems. In this atlas it is the worked example of sensing done right: a genuine physical measurement making a narrow, validated diagnostic claim. It is deliberately contrasted with consumer scanners (e.g. the AngioCode and Neko entries) that extend a real signal into unvalidated 'vascular-age' or whole-body claims.
Origin & lineage
MESI d.o.o. (Slovenia) makes the ABPI MD, an automated oscillometric ankle-brachial index (ABI) device that measures arm and ankle pressures simultaneously to screen for peripheral artery disease.
Claimed mechanism
Three cuffs (both arms and one ankle, cycled per limb) inflate and the device reads oscillometric pressure pulsations to determine systolic pressures, then computes the ABI as the ratio of ankle to higher brachial systolic pressure. A low ABI (about 0.90 or below) flags reduced lower-limb perfusion consistent with peripheral artery disease.
Plausibility
Plausible / established (narrow) — the underlying ABI is an established perfusion index and the automated oscillometric measurement is validated for screening, with accuracy limits in calcified or non-compressible vessels.
Evidence — grade B
Graded B because the automated oscillometric ABI has been compared against the hand-held Doppler reference in multicentre clinical data (Varetto 2019, n about 185, four centres) and addressed in a 2022 EJVES systematic review of portable ABI screening systems, while ABI is itself a guideline-recognized index. It is held at B rather than A because the same evidence shows agreement limits — slight ABI overestimation, a higher measurement-failure rate, and reduced reliability in calcified or non-compressible arteries — so it is a valid screen, not a perfect substitute for the reference method.
Cross-reference
This is the validated diagnostic counterpart to the overreaching consumer scanners in the atlas — contrast with AngioCode (PPG-derived 'vascular age') and the Neko whole-body scanner, which start from real signals but extend into unvalidated claims.
Market
Makers: MESI d.o.o. (Slovenia); other vendors of the automated-ABI class include Semler Scientific (QuantaFlo) and Huntleigh Healthcare (Dopplex Ability). Models: MESI ABPI MD (and integrated MESI mTABLET ABI); class examples: QuantaFlo, Huntleigh Dopplex Ability. Price: Not specified in source (professional clinical device, not a consumer wearable).
Kernel — keep vs set aside
Keep — real substrate
Keep the validated automated oscillometric ABI measurement as a fast, operator-light screen for peripheral artery disease — a real physical pressure measurement against an established reference index.
Set aside — claim
Set aside only any extension of the ABI signal beyond its validated PAD-screening role into general 'vascular-age', 'longevity', or whole-body wellness framing, which the validation evidence does not cover.
Regulatory status by jurisdiction
Registration or clearance is a market-access fact, never proof of efficacy.
US — FDA
Automated oscillometric ABI devices are regulated as a 510(k)-cleared class in the US (e.g. QuantaFlo); FDA clearance status specific to the MESI ABPI MD is not confirmed in the fetched sources — Not specified in source.
EU — MDR
MESI markets the ABPI MD as CE-marked in the EU; specific MDR certificate details not confirmed in the fetched sources.
Varetto et al. 2019 (J Non Invasive Vasc Invest; four-centre prospective study, n about 185) found the MESI ABPI MD a valid PAD-screening method against standard Doppler, while noting slight ABI overestimation and a higher failure rate. The 2022 EJVES systematic review evaluated portable ABI systems for a PAD population-screening programme. Together they support a B-grade diagnostic-validity claim (validation plus systematic-review context), not a high-certainty equivalence to the Doppler reference.